Floatz logo

Yttrium-90 Conjugated Chimeric G250

Kidney Cancer

Ludwig Institute for Cancer ResearchradiopharmaceuticalPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

70 Active assets in the Kidney Cancer cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
Dartmouth-Hitchcock Medical Center
Phase 3BBB
Girentuximab
Memorial Sloan Kettering Cancer Center
Phase 3BB
Girentuximab
Heidelberg Pharma AG
Phase 3BB
FILGRASTIM
National Institutes of Health Clinical Center (CC)
Phase 3BB
FLUOROURACILUM
Medical Research Council
Phase 3BB

View all 50 →

Same molecule, other indications

Yttrium-90 Conjugated Chimeric G250 is also rated in:

renal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →